• Something wrong with this record ?

Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer's Disease

M. Zverova, E. Kitzlerova, Z. Fisar, R. Jirak, J. Hroudova, H. Benakova, P. Lelkova, P. Martasek, J. Raboch,

. 2018 ; 15 (10) : 938-950. [pub] -

Language English Country United Arab Emirates

Document type Journal Article, Research Support, Non-U.S. Gov't

BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder with a complex pathogenesis and a common occurrence of comorbid diseases such as depression. It is accepted that the presence of the ε4 allele of the gene that encodes apolipoprotein E (APOE) is the strongest genetic risk factor for the development of sporadic AD. Melatonin, cortisol, homocysteine, and prolactin are presumed to be risk factors or biomarkers for stress- and age-related disorders. OBJECTIVE: The interplay between the APOE genotype and plasma biomarkers was examined in patients with AD presenting with or without depression to contribute to understanding the interdependence of various molecular mechanisms in the pathophysiology of AD. METHOD: The APOE genotype and morning plasma melatonin, cortisol, homocysteine, and prolactin concentrations were measured in 85 patients with AD and 44 elderly controls. RESULTS: A significant association between AD and the allele (ε4) or genotype (ε3/ε4 or ε4/ε4) frequencies of APOE was confirmed. Plasma homocysteine and cortisol levels were significantly increased in patients with AD compared to those in controls, independent of the presence of comorbid depressive symptoms or the severity of dementia. Significantly lower plasma melatonin concentration was found in patients with AD but not in controls, who were noncarriers of the APOE ε4 allele, regardless of the presence of depression or the severity of dementia in AD. CONCLUSION: Our findings indicate the existence of a little-known specific APOE-mediated mechanism that increases the plasma melatonin level in a subgroup of patients with AD who are carriers of the APOE ε4 allele.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045432
003      
CZ-PrNML
005      
20200113082217.0
007      
ta
008      
200109s2018 ts f 000 0|eng||
009      
AR
024    7_
$a 10.2174/1567205015666180601090533 $2 doi
035    __
$a (PubMed)29852871
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ts
100    1_
$a Zverova, Martina $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
245    10
$a Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer's Disease / $c M. Zverova, E. Kitzlerova, Z. Fisar, R. Jirak, J. Hroudova, H. Benakova, P. Lelkova, P. Martasek, J. Raboch,
520    9_
$a BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder with a complex pathogenesis and a common occurrence of comorbid diseases such as depression. It is accepted that the presence of the ε4 allele of the gene that encodes apolipoprotein E (APOE) is the strongest genetic risk factor for the development of sporadic AD. Melatonin, cortisol, homocysteine, and prolactin are presumed to be risk factors or biomarkers for stress- and age-related disorders. OBJECTIVE: The interplay between the APOE genotype and plasma biomarkers was examined in patients with AD presenting with or without depression to contribute to understanding the interdependence of various molecular mechanisms in the pathophysiology of AD. METHOD: The APOE genotype and morning plasma melatonin, cortisol, homocysteine, and prolactin concentrations were measured in 85 patients with AD and 44 elderly controls. RESULTS: A significant association between AD and the allele (ε4) or genotype (ε3/ε4 or ε4/ε4) frequencies of APOE was confirmed. Plasma homocysteine and cortisol levels were significantly increased in patients with AD compared to those in controls, independent of the presence of comorbid depressive symptoms or the severity of dementia. Significantly lower plasma melatonin concentration was found in patients with AD but not in controls, who were noncarriers of the APOE ε4 allele, regardless of the presence of depression or the severity of dementia in AD. CONCLUSION: Our findings indicate the existence of a little-known specific APOE-mediated mechanism that increases the plasma melatonin level in a subgroup of patients with AD who are carriers of the APOE ε4 allele.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a Alzheimerova nemoc $x krev $x genetika $7 D000544
650    _2
$a apolipoproteiny E $x genetika $7 D001057
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genotyp $7 D005838
650    _2
$a homocystein $x krev $7 D006710
650    _2
$a lidé $7 D006801
650    _2
$a hydrokortison $x krev $7 D006854
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melatonin $x krev $7 D008550
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prolaktin $x krev $7 D011388
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kitzlerova, Eva $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Fisar, Zdenek $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Jirak, Roman $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Hroudova, Jana $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Benakova, Hana $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Lelkova, Petra $u Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Martasek, Pavel $u Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Raboch, Jiri $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
773    0_
$w MED00008816 $t Current Alzheimer research $x 1875-5828 $g Roč. 15, č. 10 (2018), s. 938-950
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29852871 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113082549 $b ABA008
999    __
$a ok $b bmc $g 1483701 $s 1084105
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 15 $c 10 $d 938-950 $e - $i 1875-5828 $m Current Alzheimer research $n Curr Alzheimer Res $x MED00008816
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...